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Aspergillus
Genus of filamentous, ubiquitous fungi, commonly isolated from soil, plant
debris, and indoor air. Aspergillus was first described in 1729 by Pier Antonio
Micheli, an Italian priest and biologist who was the first person to attempt the sci-
entific study of fungi. Micheli opposed the idea of "spontaneous generation" by
showing that fungal spores grown on a medium would produce the same kind of
fungus. The shape of Aspergillus reminded him of an aspergillum (from the Latin
aspergere, "to scatter"), a device used for sprinkling holy water during a liturgi-
cal service.
Sources: Dorland's illustrated medical dictionary. 30th ed. Philadelphia: Saunders; 2003
and the Illinois Mycological Association, available from http://www.ilmyco.gen.chicago.il.us/
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Conidiophore of Aspergillus fumigatus.
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